Fig. 4: Tornado plot showing types of AEs in patients receiving dostarlimab + chemotherapy and pembrolizumab + chemotherapy (safety population as of July 7, 2023). | Nature Communications

Fig. 4: Tornado plot showing types of AEs in patients receiving dostarlimab + chemotherapy and pembrolizumab + chemotherapy (safety population as of July 7, 2023).

From: Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial

Fig. 4

*Subjects who had a fatal AE recorded and died were not recorded as due unequivocally to disease under study. †Pneumonitis; immune-related pneumonitis, urosepsis. ‡Myelosuppression, respiratory failure. §No new immune-related deaths were observed. AE adverse event, CT chemotherapy, IO immuno-oncology agent, ir immune-related, SAE serious adverse event.

Back to article page